• 목록
• 답변

ARBORMED is developing a treatment for Wilson's disease, a rare disease, as its main pipeline. Wilson's disease is a disease in which copper accumulated in the body
 is not released due to genetic abnormalities, causing complications in various liver diseases. It is considered a relatively common rare disease, but there has been no fundamental treatment
for 110 years since this disease was known. All it is to succeed in the initial diagnosis and perform liver transplantation.

ARBORMED is conducting both microbial-based Noble Target R&D and complex generic business in the U.S. to target Wilson's disease, which is impregnable.
Im Weonbin (CTO, photo), a former head of Dong-A Pharmaceutical Research Institute, joined hands in 2020 with co-CEO Park Kyo-jin, who agreed that he should have his own physical strength
to participate in the 100-year-old fight against Wilson's disease.

- The meaning or background of the company name "ARBORMED"

▲ In the U.S. state of Michigan, oak trees are called "Arbor Trees." On top of that, it was named after Ann Arbor, Michigan, where the first business of founder Park Kyo-jin began.
ARBORMED is a new drug development company that specializes in developing treatments for rare and incurable diseases.

- Please explain by selecting a peer-group at home and abroad If there is a company that has the closest business model.

▲ It is difficult to pick comparative companies in Korea. Overseas, there are Vertex Pharmaceuticals, BioMarine, and Ultragenyx Pharmaceuticals in the United States.

-C-level or core members in the organization

▲Co-CEO Park Kyo-jin has been a co-founder of MedCI, an American new drug licensing consulting firm. Lego Chem Bio and TakedaHe is a business development expert
who conducted consulting on about 30 new drug global licensing deals, including pharmaceutical global licensing deals.

Eun So-young, head of the research headquarters, is an expert who has been in charge of early research on immuno-cancer drugs and genetic immune diseases
for 20 years at the Green Cross Mokam Research Institute.

Park Eok, head of the development division, is a person who has experienced from early research to preclinical studies such as anticancer drugs and metabolic disease treatments
for 17 years at LG Life Sciences (currently LG Chem) and Mitoymunteraputics.
Yoon Kang-seok, head of the management headquarters, is a financial expert who imprisoned accounting audits from big 4 accounting firms in Korea through work at public institutions
and listed companies and has experience in conducting multiple IPOs.

-Please introduce Wilson's disease treatment and main pipeline

▲ARBM-101 targets Wilson's disease, a microbial-based treatment for rare diseases. It was introduced by the Helmholtz Institute in Germany.
The mechanism of ARBM-101 alleviates symptoms of cirrhosis by selectively binding microorganisms to copper in the body and discharging them into the feces.

It is expected that the Noble target and the first class injection in the family can contribute to prolonging the life of Wilson's disease patients and improving the quality of life.
 It plans to enter clinical trials in the United States in the second half of 2023. It is also planning to promote global licensing in the first phase of clinical trials in the first half of 2024.

ARBM-201 is a treatment for acute respiratory distress syndrome (ARDS). It is in progress in collaboration with Yonsei University Medical Center. ARDS is a pulmonary edema disease
that causes difficulty breathing due to water filling the alveoli, and has a mortality rate of about 40%, but there is no effective treatment.
It entered the main clinical trial in the first half of 2023 and is planning to license in 2025. In addition, there is also ARBM-301, which targets congenital hearing loss treatments.

- If you update your organization's R&D workforce ratio, annual R&D spending ratio, etc

▲ Currently, 50% of our workforce is R&D. It also spends about 50% of its total expenditure on R&D. It is increasing every year to 50% in 2020 and 53% in 2021.

- What is the composition of major financial investors (FI) and key equity ratios?

▲ Major FI investors  include the Korea Development Bank and SBI Investment. The stakes are 10.53% and 9.51%, respectively.
Series B was completed in November last year and has raised about 27 billion won so far. It also received 6 billion won in strategic investment (SI)
from Ildong Pharmaceutical. It plans to attract 15 billion won in Series C in the first half of 2023.

- Current status of collaboration and business development with domestic and foreign partners and the future of ARBORMED?

▲ It is jointly developing a new anticancer drug with SI investor Ildong Pharmaceutical. Ultimately, it aims to grow into a pharmaceutical company specializing
in rare diseases that directly licenses and sells new drugs developed by itself in the United States.

What else do you want to say?

▲ ARBORMED also has a business model that selects a highly profitable complex generic, obtains FDA approval in the United States, registers drug prices, and distributes finished drugs.
When FDA approval is completed, it expects annual sales of about 20 billion won and an operating profit of 20% per item in the U.S. market. Based on the five items,
the total annual sales are expected to be about 100 billion won and EBITDA 20 billion won.

-Introduction of CTO

▲ Co-CEO Im Weon-bin is a former head of Dong-A Pharmaceutical's (Dong-A ST) New Drug Research Institute and has gained experience in the entire process from researching new drugs
 for various diseases to licensing at Dong-A Pharmaceutical Research Institute for 30 years. It has applied for and registered more than 20 patents, including Teddyzolid antibiotics and
metabolic diseases approved by the FDA. He won the King Sejong Award (Patent Office) for patent technology and the Korea New Drug Development Award (Minister of Health and Welfare).